Assessing immunotherapy start-ups

A Boston based PE company aiming to expand its investment portfolio in cancer medicines requested a second opinion on four start-ups in immunotherapy. By linking 14 scientific knowledge bases, patents and scientific articles, Entis not only provided the required insights, but also identified a candidate that was superior to the original four. Eventually, the PE company invested in this company.

best cases

Sustainable Development Investments

Entis generates SDI classifications for thousands of companies.

Frontier technologies

By using our technology, a European asset manager was able to quickly identify frontier technology companies.

Immunotherapy start-ups

A private equity firm was able to assess immunotherapy start-ups using our AI powered data factory.

New technologies

A large European specialty chemicals company used our data factory to discover highly promising new technologies.